Current approach to Waldenström Macroglobulinemia
Source : https://www.sciencedirect.com/science/article/pii/S2468294222000181?via=ihub
Waldenström macroglobulinemia (WM) is a distinct lymphoplasmacytic lymphoma with a circulating monoclonal IgM protein. * WM is associated with a variety of clinical manifestations, heterogeneous clinical course, and there are...
Relevance: This review summarizes the current literature pertaining to the diagnosis, prognosis, and the treatment of WM.
The Impact of B‐cell Directed Therapy on SARS‐CoV‐2 Vaccine Efficacy in CLL
Source : https://onlinelibrary.wiley.com/doi/10.1111/bjh.18088
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between...
Conclusion/Relevance: Prior reports evaluating SARS-CoV-2 vaccine efficacy in CLL used semiquantitative measurements of Anti-S to evaluate immunity, however, neutralization assays were used to assess functional immunity in the trials leading to vaccine approval. Here, we identified decreased rates of seroconversion in vaccinated CLL patients and...
Utility of Bruton's Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström's Macroglobulinemia)
Source : https://www.hindawi.com/journals/ah/2022/1182384/
Of the variety of immunoglobulin related amyloidosis (AL), immunoglobulin M (IgM) related AL represents only 6 to 10% of affected patients, and the majority of these cases are associated with...
Conclusion/Relevance: We retrospectively evaluated the tolerability and effectiveness of BTK inhibitors ibrutinib and acalabrutinib therapy in (n = 4) patients with IgM-related AL amyloidosis with underlying WM. Treatment was well tolerated with both hematologic and organ response in patients with AL amyloidosis in the setting of WM. Atrial...
-
Leukemia and Lymphoma Connect4yrKey Points • Source: Advances in Hematology • Conclusions: “All patients evaluated had the MYD88 mutation. This may explain the good response to BTK inhibitors therapy in our series. BTK inhibitors should be further Show More
Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798964/
Haifeng Yu,# 1 , 2 , # Haiying Kong,# 3 , # Cong Li,# 1 , 2 , # Xiaowu Dong, 4 Yizhe Wu, 4 Yuxin Zhuang, 4 Shuiyun Han,...
Conclusions: In conclusion, our study results suggest that BTK inhibitors can be promising candidates for PCNSL treatment, preferring the use of ibrutinib and tirabrutinib as anti-PCNSL agents among the three inhibitors.
Discovery of Pteridine-7(8 H)-one Derivatives as Potent and Selective Inhibitors of Bruton's Tyrosine Kinase (BTK) - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35099969/
Bruton's tyrosine kinase (BTK) is an attractive therapeutic target in the treatment of cancer, inflammation, and autoimmune diseases. Covalent and noncovalent BTK inhibitors have been developed, among which covalent BTK...
Conclusion/Relevance: In U-937 xenograft models, 24a significantly inhibited tumor growth (TGI = 57.85%) at a 50 mg/kg dosage. Accordingly, 24a is a new BTK inhibitor worthy of further development.